Insight Wealth Strategies LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Insight Wealth Strategies LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 7,278 shares of the biopharmaceutical company’s stock, valued at approximately $4,092,000.

Other large investors have also added to or reduced their stakes in the company. Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $628,151,000. Acadian Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after buying an additional 326,583 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. grew its position in Regeneron Pharmaceuticals by 26.5% in the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after acquiring an additional 225,078 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on REGN. Truist Financial began coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $798.00 price target on the stock. Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $779.45.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $752.62 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $790.98. The firm has a 50-day moving average of $667.78 and a 200 day moving average of $593.79. The company has a market cap of $79.10 billion, a P/E ratio of 18.02, a PEG ratio of 2.12 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the firm posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Activity

In related news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.